{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T09:50:39Z","timestamp":1764323439623,"version":"3.46.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Zolbetuximab prolongs survival in patients with claudin18.2 (CLDN18.2)-positive gastric cancer (GC) and gastroesophageal junction cancer. However, it is associated with an increased risk of emesis, and its underlying mechanism remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>This report presents three cases of advanced GC that underwent abdominal ultrasonography (US) during zolbetuximab administration. In two patients with primary gastric lesions, severe nausea occurred during the first treatment cycle. US findings revealed increased echogenicity of the submucosal layer, enhanced layer stratification, and increased blood flow signals, which improved as the emesis subsided. During the second cycle, emesis was milder, and US findings revealed only slight changes. In the third patient who underwent total gastrectomy, no nausea or abnormal US findings were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These US findings indicate gastric tumor tissue injury due to zolbetuximab, which is associated with emesis. US is a valuable tool for further elucidating the mechanisms underlying zolbetuximab-induced emesis and may also contribute to the prediction and prevention of this adverse event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Statement<\/jats:title>\n                    <jats:p>Zolbetuximab treatment has been reported to improve survival in patients with HER2-negative, CLDN18.2-positive advanced, unresectable, or recurrent gastric and gastroesophageal junction cancers. However, it is associated with a high incidence of nausea, particularly during the first infusion, and the underlying mechanism remains unclear. We present three cases of advanced or recurrent gastric cancer treated with zolbetuximab, during which abdominal ultrasonography (US) was performed. In two cases with primary gastric tumors, US revealed characteristic changes in the gastric wall at the onset of nausea, suggestive of edema and inflammation. These changes appeared prior to the symptoms and resolved as nausea improved. Nausea during the second infusion was milder, with less pronounced US changes. The third case includes a patient who had undergone total gastrectomy; the patient did not experience nausea, and no gastrointestinal changes were observed on US. This is the first report to describe US findings associated with zolbetuximab-induced nausea. These observations suggest that gastric wall changes detectable using US are closely linked to nausea and may reflect underlying gastric injury. This report also highlights the potential of bedside US monitoring to help predict and prevent nausea during zolbetuximab therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1686245","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T09:48:24Z","timestamp":1764323304000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Ultrasound-detected gastric changes related to zolbetuximab-induced emesis: a case series"],"prefix":"10.3389","volume":"15","author":[{"given":"Kazuaki","family":"Harada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiho","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Sawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutsumi","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30354-3","article-title":"Gastric cancer","volume":"388","author":"Van Cutsem","year":"2016","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"17588359231217967","DOI":"10.1177\/17588359231217967","article-title":"Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer","volume":"16","author":"Kubota","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-017-0473-4","article-title":"Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer","volume":"10","author":"Singh","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.005","article-title":"FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma","volume":"32","author":"Sahin","year":"2021","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz199","article-title":"A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study","volume":"30","author":"Tureci","year":"2019","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2024.100128","article-title":"Managing zolbetuximab-induced nausea and vomiting: a proposal for a pragmatic approach in clinical practice","volume":"7","author":"Shimozaki","year":"2025","journal-title":"ESMO Gastrointestinal Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s10396-022-01236-0","article-title":"Basic practices for gastrointestinal ultrasound","volume":"50","author":"Nishida","year":"2023","journal-title":"J Med Ultrason (2001)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1148\/radiology.181.1.1653442","article-title":"Scirrhous carcinoma of the stomach versus hypertrophic gastritis: findings at endoscopic US","volume":"181","author":"Fujishima","year":"1991","journal-title":"Radiology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2024.08.005","article-title":"Effect of antiemetics on zolbetuximab-induced gastric injury and emesis in ferrets","volume":"156","author":"Kinugasa","year":"2024","journal-title":"J Pharmacol Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"943618","DOI":"10.1155\/2015\/943618","article-title":"Management of chemotherapy induced nausea and vomiting in patients on multiday cisplatin based combination chemotherapy","volume":"2015","author":"Ranganath","year":"2015","journal-title":"BioMed Res Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29110650","article-title":"Olanzapine for the prevention and treatment of chemotherapy-induced nausea and vomiting: A review to identify the best way to administer the drug","volume":"29","author":"Zhang","year":"2022","journal-title":"Curr Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"175379","DOI":"10.1016\/j.ejphar.2022.175379","article-title":"Gastrointestinal inflammation plays a critical role in chemotherapy-induced nausea and vomiting","volume":"936","author":"Chen","year":"2022","journal-title":"Eur J Pharmacol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1686245\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T09:48:25Z","timestamp":1764323305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1686245\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":21,"alternative-id":["10.3389\/fonc.2025.1686245"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1686245","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"article-number":"1686245"}}